{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:16:30Z","timestamp":1772068590869,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Prostate cancer is the second most common cancer and the leading cause of cancer\u2010related deaths in men. Patients with metastatic castration\u2010resistant prostate cancer (mCRPC) with diffuse bone metastases have limited treatment options due to severe hematological toxicity risks. This study evaluates the safety and efficacy of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA radioligand therapy (RLT) in this high\u2010risk group within an Asian population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective analysis of 48 mCRPC patients with PSMA\u2010avid diffuse bone metastases treated with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010RLT between May 9, 2018 and Jan 10, 2023. Patients received up to 4 to 6 initial therapy cycles, with additional cycles considered for those who responded initially but later progressed. Primary and secondary endpoints included overall survival (OS), PSA progression\u2010free survival (PFS), PSA response, clinical response, and toxicity assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median OS was 9.3 months. Any PSA response was observed in 75% of patients. Notably, 48% achieved a \u226550% PSA reduction, correlating with a longer median OS (11.6\u00a0vs. 8.6 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.03). Median PSA PFS was 3.2 months, with improved outcomes observed in patients achieving \u226550% PSA reduction (6.0\u00a0vs. 1.8 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001). Pain relief was reported in 43% of patients, with a median pain score reduction of 5 points. The most common adverse effect was hepatotoxicity, with anemia in 27%, neutropenia in 27%, and thrombocytopenia in 21%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010RLT demonstrates clinically meaningful benefits in survival and symptom management with an acceptable safety profile for mCRPC patients with extensive bone metastases. These findings support [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu\u2010PSMA\u2010RLT as a viable treatment option for this challenging population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.14195","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T23:50:10Z","timestamp":1748562610000},"page":"639-646","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Lutetium\u2010177 PSMA Radioligand Therapy in Metastatic Castration\u2010Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)"],"prefix":"10.1111","volume":"21","author":[{"given":"Cherie Wei Qi","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Diagnostic Imaging National University Health System  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Ming","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital  Singapore Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore Singapore"},{"name":"Department of Neuroradiology Singapore General Hospital  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie Wing\u2010Chuen","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital  Singapore Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron Kian\u2010Ti","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital  Singapore Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Chee Eng","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital  Singapore Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene Yu Lin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital  Singapore Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Ying","family":"Tham","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital  Singapore Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[{"name":"Duke\u2010NUS Medical School  Singapore Singapore"},{"name":"Division of Medical Oncology National Cancer Centre Singapore  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvin Seng Cheong","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Haematology\u2010Oncology National University Cancer Institute  Singapore Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[{"name":"Duke\u2010NUS Medical School  Singapore Singapore"},{"name":"Department of Urology Singapore General Hospital  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[{"name":"Duke\u2010NUS Medical School  Singapore Singapore"},{"name":"Department of Urology Singapore General Hospital  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue Ping","family":"Thang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging Singapore General Hospital  Singapore Singapore"},{"name":"Duke\u2010NUS Medical School  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1296"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67149-2"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602767"},{"key":"e_1_2_12_7_1","first-page":"81","article-title":"Prostate\u2010specific Membrane Antigen Expression in Normal and Malignant human Tissues","volume":"3","author":"Silver D. A.","year":"1997","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00278-7"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0145-8"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001179"},{"key":"e_1_2_12_13_1","unstructured":"US Department of Health and Human Services.Common Terminology Criteria for Adverse Events. Version 5. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5X11.pdf(2017)."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(01)00409-2"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13944"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.05.004"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164017"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.20845"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.004"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081974"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262017"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00638-1"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05778-w"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1059122"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T20:31:34Z","timestamp":1762201894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ajco.14195"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14195","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"2025-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}